Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Liabilities and Shareholders Equity (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Liabilities and Shareholders Equity for 14 consecutive years, with $318.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 27.63% year-over-year to $318.9 million, compared with a TTM value of $1.4 billion through Dec 2025, down 29.57%, and an annual FY2025 reading of $318.9 million, down 27.63% over the prior year.
  • Liabilities and Shareholders Equity was $318.9 million for Q4 2025 at Fate Therapeutics, down from $343.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.0 billion in Q1 2021 and bottomed at $318.9 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $641.0 million, with a median of $577.3 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 224.94% in 2021, then plummeted 30.57% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $921.5 million in 2021, then decreased by 23.43% to $705.6 million in 2022, then dropped by 28.25% to $506.2 million in 2023, then dropped by 12.94% to $440.7 million in 2024, then dropped by 27.63% to $318.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for FATE at $318.9 million in Q4 2025, $343.7 million in Q3 2025, and $371.6 million in Q2 2025.